It is very uncertain whether single‐dose, preoperative MMC‐EMDA changes serious adverse events compared with single‐dose, postoperative MMC‐PD (very low certainty).
It is very uncertain whether single‐dose, preoperative MMC‐EMDA changes serious adverse events compared with TURBT alone (very low certainty).
Degarelix showed no clear difference in serious adverse events compared with standard androgen suppression therapy (low certainty).
Early showed no clear difference in serious adverse events compared with deferred AST (low certainty).
It is very uncertain whether antimicrobial changes serious adverse events compared with placebo or no antibiotics (very low certainty).
Pazopanib leads to higher serious adverse events (Grade 3 or 4) compared with placebo (targeted agent versus placebo) (high certainty).
The intervention showed no clear difference in serious adverse events (SAEs) ‐ Network included 31 pairwise… (moderate certainty).